49 results on '"Udeze, C."'
Search Results
2. CO34 Mortality and Clinical Complications Among Patients with Transfusion-Dependent Beta-Thalassemia in France
3. CO188 Mortality and Clinical Complications Among Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in France
4. EE111 Indirect Cost Burden for Individuals Living with Transfusion-Dependent Beta-Thalassemia in Europe
5. EE278 Model-Projected Long-Term Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) Gene-Edited Therapy in Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United Kingdom
6. EE717 Healthcare Resource Utilization Among Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in France
7. EE262 Indirect Cost Burden for Individuals Living with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Europe
8. EE109 Healthcare Resource Utilization Among Patients with Transfusion-Dependent Beta-Thalassemia in France
9. Switch Rates and Total Cost of Care Associated with Apremilast and Biologic Therapies in Biologic-Naive Patients with Plaque Psoriasis
10. EE62 Healthcare Resource Utilization Among Patients with Transfusion-Dependent Beta-Thalassemia in Germany
11. EE458 Modelling Long-Term Clinical Outcomes of Patients with Transfusion-Dependent Beta-Thalassemia in the United States
12. EE194 Modelling Long-Term Clinical Outcomes of Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in the United States
13. EE15 Economic Burden of Transfusion-Dependent Beta-Thalassemia in the United States
14. P1703: ECONOMIC BURDEN OF TRANSFUSION-DEPENDENT BETA-THALASSEMIA IN THE UNITED STATES
15. P1704: PROJECTED LIFETIME ECONOMIC BURDEN OF SEVERE SICKLE CELL DISEASE IN THE UNITED STATES
16. PB2339: PROJECTED LIFETIME ECONOMIC BURDEN OF TRANSFUSION DEPENDENT BETA-THALASSEMIA IN THE UNITED STATES
17. EE369 Healthcare Resource Utilization Among Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in Canada
18. EE295 Economic Burden Associated With Managing Patients With Sickle Cell Disease Receiving Frequent Red Blood Cell Transfusions in the United States
19. Modeling cache performance for embedded systems
20. EE132 Economic Outcomes and Real-World Adherence of Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises Treated With L-Glutamine, Voxelotor, and Crizanlizumab in the United States.
21. EE528 Healthcare Resource Utilization Among Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in England
22. EE404 Healthcare Resource Utilization Among Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Italy
23. EE287 Healthcare Resource Utilization Among Patients with Transfusion-Dependent Beta-Thalassemia in England
24. EE173 Economic Evaluation of Exagamglogene Autotemcel (EXA-CEL) Gene-Edited Therapy in Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises
25. EE178 Healthcare Resource Utilization Among Patients with Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in Germany
26. EE58 Healthcare Resource Utilization Among Patients with Transfusion-Dependent Beta-Thalassemia in Italy
27. P2 Economic Evaluation of Exagamglogene Autotemcel (EXA-CEL) Gene-Edited Therapy in Patients with Transfusion-Dependent Beta-Thalassemia
28. Tendon material properties cannot be predicted by the material properties of the tendon fascicles: A5
29. PSS15 REAL-WORLD COSTS IN BIOLOGIC NAIVE PSORIATIC ARTHRITIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE
30. PSS23 DISEASE BURDEN IN PATIENTS WITH MILD PSORIASIS: GROUP CONCEPT MAPPING
31. PSS14 REAL-WORLD COSTS IN BIOLOGIC-NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR BIOLOGICS IN A US HEALTHCARE CLAIMS DATABASE
32. Detection of Prostate Cancer Using Radial/Axial Scanning of 2D Trans-rectal Ultrasound Images
33. PNS245 DEVELOPING PRIORITIES FOR THE COMMUNITY ENGAGEMENT TRAINING OF HEALTHCARE PROFESSIONAL STUDENTS
34. PMS37 RATES OF REAL-WORLD TREATMENT SWITCHING AMONG BIOLOGIC-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS INITIATING APREMILAST OR BIOLOGIC TREATMENT: RESULTS FROM A US CLAIMS DATABASE
35. PSS6 COMPARISON OF TREATMENT SWITCHING AMONG BIOLOGIC-NAIVE PSORIASIS PATIENTS INITIATING APREMILAST OR BIOLOGIC TREATMENT: RESULTS FROM A US CLAIMS DATABASE
36. Towards complex dynamic fog network orchestration using embedded neural switch
37. Towards complex dynamic fog network orchestration using embedded neural switch.
38. Reactor Full Automation in Temperature System
39. Performance Analysis of R-DCN Architecture for Next Generation Web Application Integration
40. Capacity for sliding between tendon fascicles decreases with ageing in injury prone equine tendons: A possible mechanism for age-related tendinopathy?
41. Clinical burden and healthcare resource utilization associated with managing transfusion-dependent β-thalassemia in France.
42. Embedding Health Equity Science at the Core of Public Health Practice.
43. Correction to: Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
44. Economic and Clinical Burden of Managing Sickle Cell Disease with Recurrent Vaso-Occlusive Crises in the United States.
45. Economic and clinical burden of managing transfusion-dependent β-thalassemia in the United States.
46. Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis.
47. Impact of Outpatient vs Inpatient ABSSSI Treatment on Outcomes: A Retrospective Observational Analysis of Medical Charts Across US Emergency Departments.
48. Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis.
49. Capacity for sliding between tendon fascicles decreases with ageing in injury prone equine tendons: a possible mechanism for age-related tendinopathy?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.